

TF

Date February 28, 2006

I hereby certify that, on the date indicated above, I deposited this paper with identified attachments and/or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by "First Class Mail" service.

Kim Blum
Name (Print)

Kim Blum
Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: WADA et al.)	Examiner:	Unassigned
)		
Application Number: 10/563,074)	Group Art Unit:	Unassigned
)		
Filed: December 29, 2005)	Confirmation No.:	Unassigned
)		
Docket No.: 3190-087)	Customer No.:	33432

For: METHOD FOR INHIBITING TELOMERASE ACTIVITY AND INHIBITOR THEREOF

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

February 28, 2006

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO/SB/08. Pursuant to the current United States Patent and Trademark Office rules, no copies of U.S. Patents/Patent Application Publications are provided.

This Information Disclosure Statement is being submitted before expiration of the three-month period following filing of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. *See* 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO/SB/08 be made of record therein and appear

Information Disclosure Statement
U.S. Patent Application No. 10/563,074


on the first page of any patent to issue therefrom.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in this application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.


Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

It is believed that no fee is required to make this a complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 50-0925.

Respectfully submitted,


Luke A. Kilyk
Reg. No. 33,251

Atty. Docket No.: 3190-087
KILYK & BOWERSOX, P.L.L.C.
400 Holiday Court, Suite 102
Warrenton, VA 20186
Tel.: (540) 428-1701
Fax: (540) 428-1720
Enclosures: PTO/SB/08 w/38 documents



PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/563,074
				Filing Date	December 29, 2005
				First Named Inventor	WADA et al.
				Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	3190-087
Sheet	1	of	3		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number - Kind Code ² (if known)				
		US-2002/0193289 A1	12/19/2002	Andrews		
		US-2005/0261836 A1	11/24/2005	Meng et al.		
		US-6,686,159 B2	02/03/2004	Andrews et al.		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		WO 2001/67299 A1	09/13/2001	Daiichi Pharmaceutical Co., Ltd. and Fijitsu Ltd.		English translation
		WO 2004/005511 A1	07/07/2003	Kansai Technology Licensing Organization Co., Ltd.		Abstract only, see EP 1 553 178 A1 for English version
		WO 2002/101010 A2	06/06/2002	Sierra Sciences, Inc.		Abstract only, see US 2002/0193289 A1 for English version
		WO 2002/16657 A1	08/17/2001	Sierra Sciences, Inc.		See US 6,686,159 B2
		WO 2003/048340 A2	12/05/2002	Vertex Pharmaceuticals Inc.		Abstract only, see US 2005/0261836 A1 for English version
		EP 1 553 178 A1	07/13/2005	Kansai Technology Licensing Organization Co., et al.		
Examiner Signature			Date Considered			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/563,074
				Filing Date	December 29, 2005
				First Named Inventor	WADA et al.
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	2	of	3	Attorney Docket Number	3190-087

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city, and/or country where published.	T ²
		KAWAGOE et al., "Raloxifene Inhibits Estrogen-induced Up-regulation of Telomerase Activity in a Human Breast Cancer Cell Line," THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 278, Vol. 44, Oct. 31, 2003, pp. 43363-43372.	
		KANG et al., "Akt Protein Kinase Enhances Human Telomerase Activity Through Phosphorylation of Telomerase Reverse Transcriptase Subunit," THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 274, No. 19, May 7, 1999, pp. 13085-13090.	
		SITHANANDAM et al., "3pK, a New Mitogen-Activated Protein Kinase-Activated Protein Kinase Located in the Small Cell Lung Cancer Tumor Suppressor Gene Region," MOLECULAR AND CELLULAR BIOLOGY, Vol. 16, No. 3, March 1996, pp. 868-876.	
		KELLEHER et al., "Telomerase: Biochemical Considerations for Enzyme and Substrate," TRENDS IN BIOCHEMICAL SCIENCES, Vol. 27, No. 11, November 2002, pp. 572-579.	
		LI et al., "Protein Phosphatase 2A Inhibits Nuclear Telomerase Activity in Human Breast Cancer Cells," THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 272, No. 27, July 4, 1997, pp. 16729-16732.	
		LI et al., "Telomerase is Controlled by Protein Kinase Cα in Human Breast Cancer Cells," THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 273, No. 50, December 11, 1998, pp. 33436-33442.	
		BREITSCHOPF et al., "Pro-atherogenic Factors Induce Telomerase Inactivation in Endothelial Cells Through an Akt-dependent Mechanism," FEBS LETTERS, No. 493, 2001 pp. 21-25.	
		HAENDELER et al., "Regulation of Telomerase Activity and Anti-apoptotic Function by Protein-Protein Interaction and Phosphorylation," FEBS LETTERS, No. 536, 2003, pp. 180-186.	
		SALH et al., "Dysregulation of Phosphatidylinositol 3-Kinase and Downstream Effectors in Human Breast Cancer," INT. J. CANCER, No. 98, 2002, pp. 148-154.	
		GREENBERG et al., "Selective p38 Activation in Human Non-Small Cell Lung Cancer," AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, Vol. 26, 2002, pp. 558-564.	
		WANG et al., "Overexpression of Mitogen-activated Protein Kinase Phosphatases MKP1, MKP2 in Human Breast Cancer," CANCER LETTERS xx, 2002, pp. 229-237.	
		SIVARAMAN et al., "Hyperexpression of Mitogen-activated Protein Kinase in Human Breast Cancer," J. CLIN. INVEST., Vol. 99, No. 7, April 1997, pp. 1478-1483.	
		OKA et al., "Constitutive Activation of Mitogen-activated Protein (MAP) Kinases in Human Renal Cell Carcinoma," CANCER RESEARCH, Vol. 55, No. 18, September 15, 1995, pp. 4182-4187.	
		JOHNSON, "Signal Transduction Abnormalities in Cancer Mitogen-activated Protein Kinase Regulation is Altered in Breast Cancer," J. CLIN. INVEST., Vol. 99, No. 7, April 1997, pp. 1463-1464.	
		KIM et al., "Constitutive Activation of Extracellular Signal-Regulated Kinase in Human Acute Leukemias: Combined Role of Activation of MEK, Hyperexpression of Extracellular Signal-Regulated Kinase, and Downregulation of a Phosphatase, PAC1," BLOOD, Vol. 93, No. 11, June 1, 1999, pp. 3893-3899.	
		MANDELL et al., "In Situ Visualization of Intratumor Growth Factor Signaling Immunohistochemical Localization of Activated ERK/MPA Kinase in Glial Neoplasms," AMERICAN JOURNAL OF PATHOLOGY, Vol. 153, No. 5, November 1998, pp. 1411-1423.	
		SANTEN et al., "The Role of Mitogen-Activated Protein (MAP) Kinase in Breast Cancer," THE JOURNAL OF STEROID BIOCHEMISTRY & MOLECULAR BIOLOGY, Vol. 80, No. 2, February 2002, pp. 239-256.	
		HORI et al., "Overexpression of Mitogen-activated Protein Kinase Superfamily Proteins Unrelated to Ras and AF-1 of Estrogen Receptor Alpha Mutation in Advanced Stage Human Breast Cancer," PATHOLOGY RESEARCH AND PRACTICE, Vol. 196, 2000, pp. 817-826.	
		ESTEVA et al., "Expression of erbB/HER Receptors, Heregulin and P38 in Primary Breast Cancer Using Quantitative Immunohistochemistry," PATHOLOGY ONCOLOGY RESEARCH, Vol. 7, No. 3, 2001, pp. 171-177.	
		GIOELI et al., "Activation of Mitogen-Activated Protein Kinase Associated with Prostate Cancer Progression," CANCER RESEARCH, Vol. 59, January 15, 1999, pp. 279-284.	
		REDDY et al., "Role of MAP Kinase Pathways in Primitive Neuroectodermal Tumors," ANTICANCER RESEARCH, Vol. 21, 2001, pp. 2733-2738.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/563,074
				Filing Date	December 29, 2005
				First Named Inventor	WADA et al.
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	3	of	3	Attorney Docket Number	3190-087

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city, and/or country where published.	T ²
		ALBANELL et al., "Activated Extracellular Signal-regulated Kinases: Association with Epidermal Growth Factor Receptor/Transforming Growth Factor α Expression in Head and Neck Squamous Carcinoma and Inhibition by Anti-Epidermal Growth Factor Receptor Treatments," CANCER RESEARCH, Vol. 61, September 1, 2001, pp. 6500-6510.	
		ITO et al., "Activation of Mitogen-Activated Protein Kinases/Extracellular Signal-Regulated Kinases in Human Hepatocellular Carcinoma," HEPATOLOGY, Vol. 27, No. 4, April 1998, pp. 951-958.	
		PRICE et al., "Activation of Extracellular Signal-Regulated Kinase in Human Prostate Cancer," THE JOURNAL OF UROLOGY, Vol. 162, October 1999, pp. 1537-1542.	
		LUDWIG et al., "3pK, a Novel Mitogen-Activated Protein (MAP) Kinase-Activated Protein Kinase, Is Targeted by Three MAP Kinase Pathways," MOLECULAR AND CELLULAR BIOLOGY, Vol. 16, No. 12, December 1996, pp. 6687-6697.	
		KIM et al., "Specific Association of Human Telomerase Activity with Immortal Cells and Cancer," SCIENCE, Vol. 266, December 23, 1994, pp. 2011-2015.	
		WENZ et al., "Human Telomerase Contains Two Cooperating Telomerase RNA Molecules," THE EMBO JOURNAL, Vol. 20, No. 13, 2001, pp. 3526-3534.	
		TATEMATSU et al., "A Novel Quantitative 'Stretch PCR Assay,' That Detects a Dramatic Increase in Telomerase Activity During the Progression of Myeloid Leukemias," ONCOGENE, Vol. 13, 1996, pp. 2265-2274.	
		NAKAMURA et al., "Simple, Rapid, Quantitative, and Sensitive Detection of Telomere Repeats in Cell Lysate by a Hybridization Protection Assay," CLINICAL CHEMISTRY, Vol. 45, No. 10, 1999, pp. 1718-1724.	
		MAESAWA et al., "A Rapid Biosensor Chip Assay for Measuring of Telomerase Activity Using Surface Plasmon Resonance," NUCLEIC ACIDS RESEARCH, Vol. 31, No. 2, 2003, e4, pages 1-6.	
		FRANCIS et al., "A Rapid Direct Telomerase Assay Method Using 96-Well Streptavidin Plates," BIOTECHNIQUES, Vol. 32, No. 5, 2002, pp. 1154-1160.	
		PADDISON et al., "Short Hairpin RNAs (shRNAs) Induce Sequence-Specific Silencing in Mammalian Cells," GENES & DEVELOPMENT, Vol. 16, 2002, pp. 948-958.	
Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.